Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough

This article was originally published in The Rose Sheet

Executive Summary

Robert Bertolini tapped exec VP and CFO, effective Nov. 17, company announces. Reporting to CEO Fred Hassan, Bertolini will be responsible for building a global finance team dedicated to transforming Schering into a successful international competitor, firm says. Exec, who previously served as a lead partner in PricewaterhouseCoopers' Global Pharmaceutical Industry Group, succeeds Jack Wyszomierski, who is leaving the firm to pursue other interests. Bertolini's appointment is "an important step" in implementing Schering's turnaround plan, according to the company (1"The Rose Sheet" July 14, 2003, p. 9)...

You may also be interested in...



Schering Taps Former AHP Exec Barshay To Head Consumer Health Care Unit

Schering-Plough appointed former American Home Products Senior VP Stanley Barshay as chairman of its Consumer Health Care division effective July 7

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.

UsernamePublicRestriction

Register

RS011662

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel